A Phase 2 interventional study of Betamethasone in Respiratory Distress Syndrome (RDS) and Bronchopulmonary Dysplasia (BPD), sponsored by Khang Nguyen. Not yet recruiting at 1 site in United States. Open to participants aged Up to 28 Weeks. Per ClinicalTrials.gov, last updated 2026-03-03.
Sponsored by Khang Nguyen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 324 studies in Respiratory Distress Syndrome with a site in United States — 46 open to participants now, 56 under way, 7 of them phase 3. Respiratory Distress Syndrome · United States.
Among the 324 studies in Respiratory Distress Syndrome with a site in United States, this one is the 81st largest by planned enrollment of the 250 interventional ones that give a count, is one of 15 that started in 2026, is one of 74 in phase 2, reaches primary completion later than 19 of the 55 other live ones, and was the 317th registered.
1,389 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.
Browse Respiratory Distress Syndrome studies →46 of the 324 studies in Respiratory Distress Syndrome with a site in United States are open now. Recruiting first, the newest first:
University of Alabama at Birmingham · Sites in United States
Ages 7 days–30 days
Ohio State University · Sites in United States
Ages 18+
University of Texas Southwestern Medical Center · Sites in United States
Ages 0 hrs–72 hrs
Massachusetts General Hospital · Sites in United States
Ages 18–80
Implicit Bioscience · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 196 Respiratory Distress Syndrome studies recruiting now, 116 (59%) set no upper age limit and 50 (26%) stop at 75 or younger; 52 take children under 18; 9 take healthy volunteers.
This study: Up to 28 Weeks · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
324 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 40 · Phase 2 101 · Phase 3 46 · Phase 4 6
First in 1991; this study’s year is marked. 15 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 60 across 823 interventional studies indexed under Respiratory Distress Syndrome.
Median enrollment 52 across the 250 interventional studies, 85 across the 68 observational. Of the 220 that completed or were terminated, 101 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
75 of 324 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Khang Nguyen as lead sponsor.
Khang Nguyen has 1 study filed under Respiratory Distress Syndrome — fewer than ten, so there is no comparison to draw.
20 of the studies in Respiratory Distress Syndrome with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06776783Phase 3Aerogen Pharma LimitedSafety and Efficacy of APC-0101 in Preterm Infants With Respiratory Distress Syndrome | 2027-05 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT05354141Phase 3Direct Biologics, LLCExtracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS) | 2027-11-30 |
| NCT04369599Emory UniversityTrans Thoracic Manipulation of Ventilation/Perfusion: the V/Q System | 2026-11 |
| NCT07674953University of ArkansasHow Different Levels of CPAP Affect Oxygen Delivery and Lung Expansion in Preterm Infants | 2026-12 |
Add all 20 to your calendar (.ics) → With an account.
Among the 324 studies in Respiratory Distress Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to determine if giving a steroid medication (specifically, betamethasone) after birth can help extremely premature babies (born before 28 weeks) come off breathing machines safely and reduce their risk of chronic lung disease associated with prematurity. Only babies who meet treatment criteria will receive this medication. Babies who do not meet treatment criteria will not receive medication.
The main questions it aims to answer are:
All babies in this study will:
Babies born extremely early (before 28 weeks of pregnancy) often have very immature lungs and usually need a breathing machine to stay alive. Many of these babies develop a chronic lung disease associated with prematurity called bronchopulmonary dysplasia, which can cause breathing problems that may last for months or years.
Doctors sometimes use steroid medications after birth to help reduce lung inflammation, make breathing easier, and help babies come off the ventilator sooner. One of these medications is betamethasone. Betamethasone is already commonly given to mothers before preterm birth to help babies' lungs mature.
At our hospital, betamethasone has been given after birth for more than 20 years to help some premature babies breathe better and come off a breathing machine. This study will help us learn how well this medicine works and possible side effects.
All babies born before 28 weeks gestation will be approached for enrollment in this study. Babies with lung disease severe enough according to predetermined criteria will receive betamethasone. Babies who dont have severe lung disease will not receive betamethasone.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Infants who meet clinical criteria will receive postnatal betamethasone
Drug: Betamethasone
Infants who do not meet criteria to receive treatment
Infants who meet clinical criteria will receive a 5-day course of postnatal betamethasone: 0.125 mg/kg/dose IM every 24 hours for 3 days then 0.0625 mg/kg/dose IM every 24 hours for 2 days
The rate of successful respiratory weaning
* Defined by a 20% reduction from baseline in mean airway pressure or FiO2 if patient remains intubated * or successful extubation and maintenance of extubation for 7 days after betamethasone completion
Time frame: From initiation of treatment until 7 days after treatment completion
The incidence of adverse events
The incidence of hyperglycemia (\>150 mg/dL) during administration period
Time frame: During betamethasone administration period (5 days)
The incidence of adverse events
The incidence of hypertension (requiring medication) anytime during hospitalization
Time frame: From the time of initiation of betamethasone until the time of NICU discharge or 52 weeks of age, whichever comes first
The incidence of adverse events
The incidence of gastrointestinal perforation (during or less than 72 hours after treatment completion)
Time frame: During betamethasone administration period and up to 72 hours after completion of betamethasone administration
The incidence of adverse events
The incidence of culture-positive infection that requires treatment
Time frame: From the time of initiation of betamethasone until the time of NICU discharge or 52 weeks of age, whichever comes first
The incidence of mortbidities associated with extreme prematurity
The incidence of * Severe intraventricular hemorrhage * Periventricular leukomalacia * Retinopathy of prematurity * Hemodynamically signifcant patent ductus arteriosus
Time frame: From admission until the time of NICU discharge or 52 weeks of age, whichever comes first
Anthropometric measurements
weight at the time of discharge (in grams and percentile rank using Fenton growth curve 2013 for gestational age) and at 24 months corrected age (in grams and their corresponding percentile rank for age using CDC growth chart 0-36 months)
Time frame: From discharge to 24 months corrected age
Anthropometric measurements
length at the time of discharge (in centimeters and percentile rank using Fenton growth curve 2013 for gestational age) and at 24 months corrected age (in centimeters and their corresponding percentile rank for age using CDC growth chart 0-36 months)
Time frame: From discharge to 24 months corrected age
Anthropometric measurements
Head circumference at the time of discharge (in centimeters and percentile rank using Fenton growth curve 2013 for gestational age) and at 24 months corrected age (in centimeters and their corresponding percentile rank for age using CDC growth chart 0-36 months)
Time frame: From discharge to 24 months corrected age
Neurodevelopmental outcomes
the results of evaluation utilizing the Bayley Scales of Infant Development. The minimum score is 40 and the maximun score is 160, with a higher score represents better outcome. The score of 100 is average, and 15 points represents 1 standard deviation either way.
Time frame: at 24 months corrected age
Bronchopulmonary dysplasia diagnosis
Using the 2019 Jensen criteria: * Grade 1 - nasal cannula ≤2 L/min * Grade 2 - nasal cannula \>2 L/min or noninvasive positive airway pressure * Grade 3 - invasive mechanical ventilation
Time frame: at 36 weeks corrected age
Plan to share: No
Start is estimated for Apr 2026; primary completion for Mar 2027, 11 months later.
Of 31 non-industry phase 2 interventional studies under Respiratory Distress Syndrome, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 44. This study's planned 11 months is below that.
Counting every sponsor, half of 59 studies reached it within 18 months; a quarter within 9 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Betamethasone
Respiratory Distress Syndrome →